Triventi Bio raised $92m in Series A financing to advance its lead antibody programme (TRIV-509) to clinical development.

The financiers included Atlas Venture, Cormorant Asset Management, OrbiMed and other investors. In addition to funding the TRIV-509 programme, the funds will also go towards the development of two novel antibodies. The nominations for the two candidates are expected in 2024.

TRIV-509 targets kallikernin 5 and 7, which have shown promise for the treatment of atopic dermatitis, asthma and other immunology and inflammatory indications, based on a 26 October press release.

“TRIV-509 works via a unique mechanism that directly impacts barrier dysfunction, inflammation, and itch. Novel therapeutic approaches for I&I diseases are much needed, especially for atopic dermatitis patients who generally have an inadequate response to Th2-targeted therapies,” explained Triventi’s chief scientific officer Jennifer Dovey in the 26 October press release.

The funding will be used for the development of TRIV-509 from the preclinical stage through a Phase IIa trial.

Triveni was formed by a merger between Amagma Therapeutics and Atlas Venture-backed Modify Therapeutics. The company’s pipeline uses a proprietary data platform developed with Nashville Biosciences. The platform uses both public and private datasets for drug discovery.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Multiple pharmaceutical companies have invested in expanding their immunology portfolio this year. In June, MSD acquired Prometheus Biosciences for approximately $10.8bn to bolster its immunology pipeline.

Other drugs in development for treating atopic dermatitis include Eli Lilly’s monoclonal antibody, lebrikizumab which was denied approval by the US Food and Drug Administration earlier this month.